Pancreatic Cancer Research

ResearcherBC Cancer AgencyActive in the last 2 years

Renata D’Alpino Peixoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0053-7951; OpenAlex author ID A5075109756. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2015: 4 papers · 2016: none · 2017: 3 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 15

  1. Machine learning-enhanced plasma proteomics discriminates pancreatic cancer-associated diabetes from type 2 diabetes mellitus. Co-author DOI 10.1016/j.jprot.2026.105663↗
  2. Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis. Co-author DOI 10.1136/bmjonc-2025-000766↗
  3. Current and Future Global Burden of Early-Onset Pancreatic Cancer: A Population-Based Study. Last author DOI 10.1200/go-25-00016↗
  4. Current clinical practice in the management of Brazilian patients with potentially resectable pancreatic ductal adenocarcinoma (PDAC). First author DOI 10.1002/jso.27453↗
  5. Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure. Last author DOI 10.3390/cancers15205015↗
  6. Validation of Serum MicroRNAs-19a, -24, and -29a as Potential Markers to Differentiate Pancreatic Cancer-Associated Diabetes From Type 2 Diabetes Mellitus. Co-author DOI 10.1097/mpa.0000000000002040↗
  7. Clostridium difficile Infection Leading to Intestinal Pneumatosis in a Patient with a Recent Diagnosis of Pancreatic Cancer Local Recurrence: A Case Report and… Last author DOI 10.1159/000513003↗
  8. Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report… Last author DOI 10.1159/000508533↗
  9. A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated w… Co-author DOI 10.1002/cjp2.75↗
  10. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. Co-author DOI 10.1097/coc.0000000000000193↗
  11. TWELVE YEARS OF EXPERIENCE USING CHOLECYSTOJEJUNAL BY-PASS FOR PALLIATIVE TREATMENT OF ADVANCED PANCREATIC CANCER. Co-author DOI 10.1590/0102-6720201700030009↗
  12. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Co-author DOI 10.1002/cam4.459↗
  13. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/modpathol.2015.89↗
  14. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/pas.0000000000000333↗
  15. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis. Last author DOI 10.3978/j.issn.2078-6891.2015.041↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mariana Macambira Noronha · 2 shared papers, 2025 · strength 0.56
  2. Luís Felipe Leite · 2 shared papers, 2025 · strength 0.56
  3. Victor Hugo Fonseca de Jesus · 2 shared papers, 2023–2024 · strength 0.42
  4. Maria Lúcia Corrêa‐Giannella · 2 shared papers, 2022–2026 · strength 0.42
  5. Lucas Diniz da Conceição · 1 shared paper, 2025 · strength 0.30
  6. Daniel John Renouf · 5 shared papers, 2015–2017 · strength 0.30
  7. Lucas Cardoso Lázari · 1 shared paper, 2026 · strength 0.26
  8. Giuseppe Palmisano · 1 shared paper, 2026 · strength 0.26
  9. Bishal Gyawali · 1 shared paper, 2025 · strength 0.26
  10. Erick Figueiredo Saldanha · 1 shared paper, 2025 · strength 0.26
  11. David F. Schaeffer · 4 shared papers, 2015–2017 · strength 0.22
  12. Rachel P. Riechelmann · 1 shared paper, 2024 · strength 0.20
  13. Angel Ayumi Tome Uchiyama · 1 shared paper, 2021 · strength 0.19
  14. Jefferson Rios Pimenta · 1 shared paper, 2020 · strength 0.19
  15. Maziar Riazy · 2 shared papers, 2015–2017 · strength 0.12
  16. Steve E. Kalloger · 2 shared papers, 2015–2017 · strength 0.12
  17. Marcos Belotto de Oliveira · 1 shared paper, 2017 · strength 0.08
  18. Winson Y. Cheung · 1 shared paper, 2017 · strength 0.08
  19. Tércio De Campos · 1 shared paper, 2017 · strength 0.08
  20. Sharlene Gill · 1 shared paper, 2017 · strength 0.08
  21. Maria Yi Ho · 1 shared paper, 2017 · strength 0.08
  22. Joanna M. Karasinska · 1 shared paper, 2017 · strength 0.06
  23. Basile Tessier‐Cloutier · 1 shared paper, 2017 · strength 0.06
  24. Hui‐Li Wong · 1 shared paper, 2017 · strength 0.06
  25. Hagen Fritz Kennecke · 1 shared paper, 2015 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.